To solve unmet medical needs in the treatment of relapsed/refractory cancers and genetic diseases, we utilize CRISPR-mediated single or multiplex gene editing for more efficacious or safer cell therapy products.
Our CRISPR platform allows highly efficient, low toxicity, and targeted editing of single or multiple genes, enabling expedited development of more efficacious or safer cell therapy products to solve the unmet medical needs in the treatment of relapsed/refractory cancers and genetic diseases.
To generate "universal" cell therapy products, we use state-of-the-art gene-editing technology to eliminate the expression of genes associated with immunologic incompatibility, allowing the use of allogeneic cell products to treat patients. Our optimized, highly efficient gene-editing technology could substantially reduce the manufacturing cost of applicable cell therapy products.
The currently on-going, pre-clinical development of allogeneic universal CAR-T products will enable scalable manufacturing of CAR-T cells, potentially bringing down the cost of the therapy to benefit more patients. CureGenetics' "universal cell technology platform" is capable of incorporating different CAR or TCR molecules to generate allogeneic universal CAR-T or TCR-T cell products suitable for diverse indications.
CureGenetics' "universal cell technology platform" is open for collaboration or joint development that incorporates uniquely targeted biomolecular machinery (e.g. CAR, TCR, and other molecules alike). Please contact us for opportunity to explore potential collaborations.
Advantages of allogeneic universal CAR-T
|● Available: off-the-shelf on demand with short waiting time|
|● Affordable: scalable manufacture to minimize cost|
|● Assured: pre-screened healthy donors to ensure stable quality|